Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Background: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: To determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer’s disease (AD). Methods: In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein ® , Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ 1–40 and Aβ 1–42 levels, as well as cognitive, functional, and behavioral measures were determined. Results: CSF Aβ 1–42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus –45.5 pg/mL; 95% CI: –19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ 1–42 levels were lower in the PE-treated group after each treatment period ( p < 0.05). Plasma Aβ 1–40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency ( p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase ( p < 0.05). Conclusion: PE with human albumin modified CSF and plasma Aβ 1–42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapeutic plasma exchange significantly rejuvenates the proteome and improves cognition in AD patients.534,535”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [534]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
L’examen Clinique en Psychologie
Rubé, P. (1959) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1959.13.4.989 · Cited by 3,302
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 2×
“However, the accumulation of extracellular amyloid(A ) in the form of diffuse and neuritic plaques and intracellular accumulation of phosphorylated tau in the form of neurofibrillary tangles, neuropil threads, and dystrophic neurites constitutes the most salient neuropathological feature [3].”
BackgroundNordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Cornell scale for depression in dementia
Alexopoulos, G. S., Abrams, R. C., Young, R. C., & Shamoian, C. A. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90038-8 · Cited by 2,678
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Only symptomatic therapies are available for the treatment of AD, and disease-modifying compounds are currently being tested, especially medications that target A metabolism [4, 5].”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Studies conducted in animal models showed that the elimination half-life of A between CSF and plasma is about 30 minutes [12, 15, 16].”
BackgroundHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“Although the mechanisms involved in the passage of A from CSF to plasma are not well understood, there are a number of receptors that are implicated (e.g., lowdensity lipoprotein receptor) [40], and this process seems to be modulated by APOE [41].”
BackgroundThe Overt Aggression Scale for the objective rating of verbal and physical aggression
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.35 · Cited by 1,216
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Galasko, D. R., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · PubMed · Cited by 767
Multilingual Aphasia Examination
Patterson, J. (2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_900 · Cited by 682
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
The Natural History of Alzheimer's Disease: Description of Study Cohort and Accuracy of Diagnosis
Becker, J. T. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540180063015 · Cited by 576
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Incidence and Prevalence of Dementia in the Cardiovascular Health Study
Fitzpatrick, A. L., Kuller, L. H., Ives, D. G., Lopez, O. L., Jagust, W., Breitner, J. C. S., Jones, B., Lyketsos, C., & Dulberg, C. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52058.x · Cited by 438
Self-citationPhase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 1×
“other studies and suggests that A 1–40 has a faster clearance compared to A 1–42 [37, 38].”
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00029.2003 · Cited by 326
Development of a scale for assessment of agitation following traumatic brain injury
Corrigan, J. D. (1989) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638908400888 · Cited by 281
DeMattos, R. B., Bales, K. R., Parsadanian, M., O'Dell, M. A., Foss, E. M., Paul, S. M., & Holtzman, D. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00889.x · Cited by 258
Amyloid‐β efflux from the central nervous system into the plasma
Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254
Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures
Shemin, D., Briggs, D., & Greenan, M. (2007) · Journal of Clinical Apheresis · doi:10.1002/jca.20143 · Cited by 240
Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230
Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · cited 1×
“Studies conducted in animal models showed that the elimination half-life of A between CSF and plasma is about 30 minutes [12, 15, 16].”
BackgroundAge and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200 · cited 7×
“Aggregation and accumulation of A proteins in the brain has been considered a defining pathology associated with AD [3], and it has been suggested that the sporadic form of AD is related to decreased clearance of A from the central nervous system (CNS) [6].”
BackgroundInfluentialComplications of Therapeutic Plasma Exchange: Experience With 4857 Treatments
Basic‐Jukic, N., Kes, P., Glavas‐Boras, S., Brunetta, B., Bubic‐Filipi, L., & Puretic, Z. (2005) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2005.00319.x · Cited by 185
Adverse events in apheresis: An update of the WAA registry data
Mörtzell Henriksson, M., Newman, E., Witt, V., Derfler, K., Leitner, G., Eloot, S., Dhondt, A., Deeren, D., Rock, G., Ptak, J., et al. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.01.003 · Cited by 152
Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001877 · Cited by 151 · cited 1×
“other studies and suggests that A 1–40 has a faster clearance compared to A 1–42 [37, 38].”
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J. K., for the AIBL Research Group, Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., Bush, A. I., De Ruyck, K., Dromey, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090249 · Cited by 134
Altered Amyloid Protein Processing in Platelets of Patients With Alzheimer Disease
Rosenberg, R. N., Baskin, F., Fosmire, J. A., Risser, R., Adams, P., Svetlik, D., S. Honig, L., Cullum, C. M., & Weiner, M. F. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550140019007 · Cited by 126
Boada, M., Ortiz, P., Anaya, F., & Hernández, I. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.6.1395256 · Cited by 110
Self-citationReceptor-Mediated Transport of Human Amyloid β-Protein 1–40 and 1–42 at the Blood–Brain Barrier
Poduslo, J. F., Curran, G. L., Sanyal, B., & Selkoe, D. J. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0238 · Cited by 83
Peripheral Amyloid-β Levels Regulate Amyloid-β Clearance from the Central Nervous System
Marques, M. A., Kulstad, J. J., Savard, C. E., Green, P. S., Lee, S. P., Craft, S., Watson, G. S., & Cook, D. G. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0964 · Cited by 81
β-Amyloid Dynamics in Human Plasma
Huang, Y., Potter, R., Sigurdson, W., Kasten, T., Connors, R., Morris, J. C., Benzinger, T., Mintun, M., Ashwood, T., Ferm, M., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.18107 · Cited by 74
Therapeutic Albumin Binding to Remove Amyloid-β
Costa, M., Ortiz, A. M., & Jorquera, J. I. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111139 · Cited by 52
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.003 · Cited by 43
Self-citationTherapeutic plasma exchange in neurology: 2012
Cortese, I. C. M., & Cornblath, D. R. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21266 · Cited by 43
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.009 · Cited by 36
Self-citationLallana, J. E. M., Hilario, H. R., Vidal, S. M., Lujan, I. M. S., Ballester, A. C., Soriano, J. B. E., Fernández, J. J. M., Aleixandre, A. G., Bosch, E. M., & Barreiro, A. F. (2003) · Revista de Neurología · doi:10.33588/rn.3710.2003369 · Cited by 20
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Research works printed but not linked: 4
- 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A · doi:10.1002/1531-8249(199909)46:3<412::aid-ana19>3.0.co;2-a
- Smith A, 1973, Symbol Digits Modality Test
- Kaplan E, 1983, The Boston naming test
- Costa M, 2015, J Prev Alzheimers Dis, 2, 370
Cited by
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12137 · Cited by 143
Self-citation
Metadata
- Authors
- Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., Lafuente, A., Tárraga, L., Núñez, L., Torres, M., Grifols, J. R., Ferrer, I., Lopez, O. L., & Páez, A.
- Affiliations
- Memory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain
- Hospital General Universitario Gregorio Marañón (ES)
- Banc de Sang i Teixits (ES)
- Alzheimer’s Research Corporation, Mid Atlantic Geriatric Association, Manchester, NJ, USA
- Howard University (US)
- Fundació ACE (ES)
- Grifols (Spain) (ES)
- Banc de Sang i Teixits, Barcelona, Spain
- Institut de Neuropatologia, Hospital Universitario Bellvitge, Barcelona, Spain
- Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-11-28
- Volume
- 56
- Issue
- 1
- Pages
- 129-143
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5240541
- OpenAlex
- W2559487414
- Cited by
- 94
- References
- 53
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 11 · 2023: 8 · 2022: 9 · 2021: 12 · 2020: 12 · 2019: 13 · 2018: 9 · 2017: 4
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
- Funders
- Grifols
- National Institutes of Health (UL1TR001409)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- plasma exchange, albumin replacement
- MeSH terms
- Aged, Aged, 80 and over, Albumins, Alzheimer Disease, Cognition Disorders, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Plasma Exchange, Psychiatric Status Rating Scales, Tomography Scanners, X-Ray Computed, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.